Dr. Huberman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Grafton St
Newton, MA 02459Phone+1 617-610-4097Fax+1 617-975-5665
Education & Training
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1976 - 1977
Boston University Medical CenterResidency, Internal Medicine, 1975 - 1976
University of MichiganResidency, Internal Medicine, 1972 - 1975
Tufts University School of MedicineClass of 1972
Certifications & Licensure
MA State Medical License 1975 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jul 28
Publications & Presentations
PubMed
- 54 citationsActivity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.Zofia Piotrowska, Daniel B. Costa, Geoffrey R. Oxnard, Mark S. Huberman, Justin F. Gainor
Annals of Oncology. 2018-10-01 - 38 citationsEGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.Yuri Sheikine, Deepa Rangachari, Danielle C. McDonald, Mark S. Huberman, Erik S. Folch
Clinical Lung Cancer. 2016-11-01 - 340 citationsBrain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancersDeepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan
Lung Cancer. 2015-04-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
